Teladoc Health, Inc. (NYSE: TDOC) is a leading virtual care provider that offers a wide range of telehealth services to patients around the world. The company has been growing rapidly in recent years, driven by the increasing demand for virtual care services as a result of the COVID-19 pandemic.
However, the company’s stock has been underperforming the overall market in 2022, with losses of 64% compared to the S&P 500’s 18% decline. Despite this, analysts are bullish on the stock, with a median target price of $31.50, representing a +16.99% increase from the last price of $26.93.
The service expected the TDOC stock could surge to an average price of $305.33 by the end of December 2023 and $873.42 by the end of December 2025. This article aims to provide an in-depth analysis of Teladoc Health’s current performance, future prospects, and potential risks, as well as a comparison to its competitors and alternatives.
Table of Contents
Financial Analysis
In terms of financial analysis, Teladoc Health Inc has been making headlines for its stock price predictions and forecasts. A service recently expected the TDOC stock could surge to an average price of $305.33 by the end of December 2023 and $873.42 by the end of December 2025. Additionally, 12-month price forecasts for Teladoc Health Inc have a median target of 31.50, with a high estimate of 45.00 and a low estimate of 24.00. The median estimate represents a +16.99% increase from the last price of 26.93.
When looking at revenue and losses, Teladoc expects its full-year 2021 revenue to hit $2.03 billion, up from previous guidance of $2.015 billion to $2.025 billion, nearly doubling its 2020 revenue. The telehealth provider estimates it delivered more than 14.7 million virtual visits in 2021, up from 10.6 million visits in 2020. However, Teladoc’s net loss in the third quarter was $73.5 million, with total losses in 2022 totaling $9.8 billion. The loss was primarily due to $9.6 billion in goodwill impairments caused by Teladoc overpaying for acquisitions during the boom years.
The debt/equity ratio, which can be defined as a measure of a company’s financial leverage calculated by dividing its long-term debt by stockholders’ equity, is another important aspect to consider. Teladoc Health debt/equity for the three months ending September 30, 2022 was 0.25.
When comparing Teladoc to its competitors, it is important to note that there are several players in the telehealth industry such as Amwell, OneMedical, Sesame Care, PlushCare, Amazon Care, and Walmart Health Virtual Care (formerly MeMD), just to name a few. Teladoc has been able to set itself apart by focusing on the whole-person virtual care, and by refreshing its app more than two years after acquiring Livongo Health for $18.5 billion. Additionally, Teladoc Health (NYSE:TDOC) has been underperforming the U.S. stock market in 2022 by a wide margin, with the S&P 500 having losses of 18% and TDOC stock down approximately 64%.
| Year | Month | Regular Price | Least Possible Price | Best Possible Price |
|---|---|---|---|---|
| 2023 | February | $39.422 | $33.5087 | $45.3353 |
| 2023 | December | $21.476 | $18.2546 | $24.6974 |
| 2024 | December | $101.523 | $86.29455 | $116.75145 |
| 2025 | December | $240.892 | $204.7582 | $277.0258 |
| 2026 | December | $449.246 | $381.8591 | $516.6329 |
| 2027 | December | $620.448 | $527.3808 | $713.5152 |
| 2028 | January | $802.928 | $682.4888 | $923.3672 |
Teladoc’s New App
Teladoc Health, a virtual care provider, recently refreshed its app more than two years after acquiring Livongo Health for $18.5 billion. The new app was introduced at the 2023 Consumer Electronics Show conference in Las Vegas. The new app is expected to have a positive impact on both revenue and user engagement for Teladoc. The company’s continual revenue growth and current stock price of around $70 per share, make it a great buy for investors.
The telehealth industry is expected to continue growing, making Teladoc a strong player in the market. In comparison to its competitors, such as Amwell, OneMedical, and PlushCare, Teladoc’s new app sets itself apart with its emphasis on whole-person virtual care. Overall, the refresh of Teladoc’s app positions the company for continued success in the competitive telehealth market.
Industry Analysis
The telehealth industry has seen significant growth in recent years, driven by the increasing adoption of virtual care and telemedicine as a result of the COVID-19 pandemic. This has led to a shift towards remote healthcare and digital health solutions, which has been a major boon for companies like Teladoc.
Industry experts predict that the global telehealth market will reach a value of $175 billion by 2026, growing at a CAGR of around 24% during the forecast period. The increasing adoption of telehealth solutions and rising demand for virtual healthcare services are some of the key factors driving this growth.
As a leader in the virtual care space, Teladoc is well-positioned to capitalize on the growth in the telehealth industry. Its recent acquisition of Livongo Health and the launch of its new app are both evidence of its commitment to staying at the forefront of this rapidly growing market. With strong financials, a strong growth score and a wide range of competitors, Teladoc is expected to continue to perform well in the coming years.
Conclusion
- Teladoc Health is a virtual care provider that recently refreshed its app more than two years after acquiring Livongo Health for $18.5 billion.
- The company has seen strong revenue growth and a strong growth score, but also faced net losses in 2022 due to goodwill impairments caused by overpaying for acquisitions during the boom years.
- The telehealth industry is expected to continue growing, with Wall Street analysts predicting that Teladoc Health’s share price could reach $47.57 by December 13, 2023.
- The service expected the TDOC stock could surge to an average price of $305.33 by the end of December 2023 and $873.42 by the end of December 2025.
- TDOC Price is 24.930 USD today, 1 year Teladoc Health Forecast: 147.29212523109 *, 5 year Teladoc Health Forecast: 802.928 *
- Based on the expected growth of the telehealth industry, Teladoc’s continual revenue growth, and its current stock price of around $70 per share, Teladoc stock is looking like a great buy right now and throughout 2022.
However, investors should also consider the company’s net losses in 2022 and the potential impact of increased competition in the virtual care market. It may be wise to conduct further research and consult with a financial advisor before making any investment decisions.
FAQs.
Q. What is the target price for teladoc?
A. The 24 analysts offering 12-month price forecasts for Teladoc Health Inc have a median target of 32.00, with a high estimate of 45.00 and a low estimate of 24.00. The median estimate represents a +18.85% increase from the last price of 26.93.
Q. Is Tdoc a Buy Sell or Hold?
A. The Teladoc Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Q. Where will Teladoc stock be in 5 years?
A. On average, Wall Street analysts predict that Teladoc Health’s share price could reach $47.57 by Dec 13, 2023.
Q. Is Teladoc stock overvalued?
A. Teladoc Health (NYSE:TDOC), a leader in whole-person virtual care, has been underperforming the U.S. stock market in 2022 by a wide margin. The S&P 500 has losses of 18% and TDOC stock is down approximately 64%.